Finance

Beta
Lists
TDOC:NYSE
Teladoc Health Inc
$7.58
-6.07%
(-0.49) 1D
$7.57
-0.13% (-0.0100)
After hours
Closed: Jun 22, 4:00:07 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TDOC...
Open
$7.94
High
$8.15
Low
$7.54
Mkt. cap
1.37B
Avg. vol.
4.43M
Volume
4.80M
52-wk high
$9.77
52-wk low
$4.40
EPS
-$0.96
Beta
2.14
Shares outstanding
180.51M
No. of employees
5K
Open
$7.94
High
$8.15
Low
$7.54
Mkt. cap
1.37B
Avg. vol.
4.43M
Volume
4.80M
52-wk high
$9.77
52-wk low
$4.40
EPS
-$0.96
Beta
2.14
Shares outstanding
180.51M
No. of employees
5K
News stories
From sources across the web
Profile
Teladoc Health, Inc. is an American telemedicine and virtual healthcare company founded in 2002. Headquartered in New York City, its services include telehealth, employer-sponsored health plans, 24/7 care, mental health, diabetes and hypertension management, primary care, prescriptions, medical opinions, AI and analytics, telehealth devices and licensable platform services. The company uses telephone and videoconferencing software and mobile apps to provide on-demand remote medical care. Teladoc Health is active in over 175 countries, and is traded on the New York Stock Exchange. It is the first and largest telemedicine company in the United States, and has acquired numerous other companies including BetterHelp in 2015, Best Doctors in 2017, and Catapult Health in 2025. Wikipedia
About Teladoc Health Inc
CEO-
Employees5.12K
Founded2002
Headquarters-
SectorHealth care
Websiteteladochealth.com
Analyst Ratings
Based on 16 analysts giving stock ratings to TDOC in the past 3 months
Hold
Buy
4
Hold
12
Sell
0
12 month forecast
Based on 16 Wall Street analysts offering 12 month price targets for TDOC in the last 3 months.
Highest
Current $7.58
$10.00 (+31.93%)
Average
$7.27 (-4.09%)
Lowest
$5.00 (-34.04%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Jailendra Singh
Truist Financial
Hold
Reiterated
$9.00
+18.7%
06/01/2026
Allen Lutz
Bank of America Securities
Buy
Maintained
$9.00
+18.7%
05/28/2026
David Roman
Goldman Sachs
Buy
Maintained
$8.00
+5.5%
05/27/2026
Kevin Caliendo
UBS
Hold
Maintained
$6.00
-20.8%
05/15/2026
Daniel Grosslight
Citi
Hold
Reiterated
$7.00
-7.7%
05/05/2026
Peter Warendorf
Barclays
Hold
Maintained
$7.00
-7.7%
05/05/2026
Charles Rhyee
TD Cowen
Hold
Reiterated
$6.00
-20.8%
05/04/2026
David Grossman
Stifel Nicolaus
Hold
Maintained
$5.50
-27.4%
04/30/2026
Sean Dodge
BMO Capital
Hold
Maintained
$5.00
-34%
04/29/2026
Elizabeth Anderson CFA
Evercore ISI
Hold
Maintained
$6.00
-20.8%
04/30/2026
Sarah James
Cantor Fitzgerald
Buy
Reiterated
$10.00
+31.9%
04/29/2026
David Larsen
BTIG
Hold
Maintained
-
-
04/30/2026
Ryan MacDonald
Needham
Hold
Reiterated
-
-
04/30/2026
Richard Close
Canaccord Genuity
Buy
Maintained
$10.00
+31.9%
04/30/2026
Stan Berenshteyn
Wells Fargo
Hold
Maintained
$6.00
-20.8%
04/30/2026
Ryan Daniels
William Blair
Hold
Maintained
-
-
04/29/2026
Lisa Gill
J.P. Morgan
Hold
Reiterated
$7.00
-7.7%
03/13/2026
George Hill
Deutsche Bank
Buy
Upgraded
$11.00
+45.1%
03/10/2026
Michael Wiederhorn
Oppenheimer
Buy
Maintained
$7.00
-7.7%
03/03/2026
Scott Schoenhaus
KeyBanc
Hold
Maintained
-
-
02/27/2026
Steven Valiquette
Mizuho Securities
Hold
Maintained
$6.00
-20.8%
02/26/2026
Jessica Tassan
Piper Sandler
Buy
Reiterated
$9.00
+18.7%
02/26/2026
Last report
Apr 29, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.28 / -$0.39
+26.66%beat
Revenue / Est. (USD)
613.84M / 611.37M
+0.41%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
631.90M
626.44M
642.27M
613.84M
Cost of goods sold
190.54M
187.18M
197.05M
197.53M
Cost of revenue
190.54M
187.18M
197.05M
197.53M
Research and development expenses
68.78M
67.57M
71.61M
67.86M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
325.61M
318.78M
305.74M
304.90M
Operating expense
487.40M
474.72M
472.19M
465.05M
Total operating expenses
677.94M
661.90M
669.24M
662.57M
Operating income
-46.04M
-35.46M
-26.97M
-48.73M
Other non operating income
8.37M
-815.00K
378.00K
-
EBT including unusual items
-40.42M
-50.22M
-33.62M
-60.84M
EBT excluding unusual items
-32.07M
-33.72M
-24.59M
-47.80M
Income tax expense
-7.76M
-715.00K
-8.48M
3.00M
Effective tax rate
19.20%
1.42%
25.21%
-4.92%
Other operating expenses
-
-
-
-
Net income
-32.66M
-49.51M
-25.14M
-63.84M
Net profit margin
-5.17%
-7.90%
-3.91%
-10.40%
Earnings per share
-0.15
-0.19
-0.10
-0.28
Interest and investment income
10.06M
7.08M
6.95M
6.49M
Interest expense
-4.47M
-4.53M
-4.95M
-5.37M
Net interest expenses
5.59M
2.56M
2.00M
1.12M
Depreciation and amortization charges
4.34M
2.61M
2.80M
2.46M
EBITDA
2.68M
10.68M
28.67M
5.48M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer